Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel-Reference-Cited by-同舟云学术

Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel

Published:2006-08 Issue:8 Volume:26 Page:1895-1900
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:ATVB

Author:

Angiolillo Dominick J.¹,Fernandez-Ortiz Antonio¹,Bernardo Esther¹,Ramírez Celia¹,Cavallari Ugo¹,Trabetti Elisabetta¹,Sabaté Manel¹,Hernández Rosana¹,Moreno Raul¹,Escaned Javier¹,Alfonso Fernando¹,Bañuelos Camino¹,Costa Marco A.¹,Bass Theodore A.¹,Pignatti Pier Franco¹,Macaya Carlos¹

Affiliation:

1. From the Division of Cardiology (D.J.A., M.A.C., T.A.B.), University of Florida, Shands Jacksonville; Cardiovascular Institute (A.F.-O., E.B., C.R., M.S., R.H., R.M., J.E., F.A., C.B., C.M.), San Carlos University Hospital, Madrid, Spain; and the Department of Mother and Child & Biology-Genetics (U.C., E.T., P.F.), University of Verona, Italy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference33 articles.

1. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting

2. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability

3. Clopidogrel for Coronary Stenting

4. Variability in platelet responsiveness to clopidogrel among 544 individuals

5. Pharmacokinetics of clopidogrel after administration of a high loading dose

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

2. Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives;Expert Opinion on Drug Metabolism & Toxicology;2022-12-02

3. One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock;Journal of Clinical Medicine;2021-10-29

4. Antiplatelet Agents;Burger's Medicinal Chemistry and Drug Discovery;2021-04-26

5. P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of randomized trials;Thrombosis Research;2021-02